Multiple Myeloma
From the Journals
Older adults with multiple myeloma face heavy burden of care
From the Journals
Initial response to novel agents preps MM patients for favorable transplant outcomes
Triplet induction outperformed doublet in early outcomes, but later outcome differences were not statistically significant.
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
From the Journals
Statins linked to improved survival in multiple myeloma
From the Journals
Age, other risk factors predict length of MM survival
From the Journals
Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma
News
FDA approves belantamab in relapsed/refractory multiple myeloma
The first-in-class drug belantamab mafodotin (Blenrep) has been approved in the United States for use in relapsed and refractory multiple myeloma...
Latest News
E.U. gives thumbs up for belantamab in R/R multiple myeloma
From the Journals
MM patients with concurrent AL show poor survival when coupled to cardiac dysfunction
Cardiac dysfunction is a major determinant of poor survival in multiple myeloma patients with concurrent light chain amyloidosis.
From the Journals
Transitioning regimen may prolong proteasome inhibitor–based therapy for MM
Transitioning from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone increased PI-based treatment adherence/...
Conference Coverage
Isa-Kd improves PFS in relapsed/refractory multiple myeloma